The earnings were hit by drop in gRevlimid sales, which dragged the overall North America business. “Our upcoming launches are expected to cushion gRevlimid revenue decline and provide long-term growth,” said Umang Vohra, MD and Global CEO, Cipla.
EBITDA for the quarter dropped 37% YoY to Rs 1,255 crore, while margins declined to 17.7%.
Segment-wise, within the One India business, branded prescriptions delivered double-digit growth of 10% YoY. Key therapies like Respiratory, Urology, Cardiac, and anti-diabetes grew at strong double-digit market growth, with the overall Chronic mix being improved to 62.3%.
In the trade generics, the performance was supported by decent execution in distribution, new introductions, and technological interventions. The business launched 8 new products in Q3FY26, including entry into sexual wellness to expand therapy coverage.
Live Events
In consumer health, anchor brands of Nicotex, Omnigel, and Cipladine maintained leadership positions in their respective market segments. “The business is driving healthy secondary growth and actively exploring opportunities to invest in products and channels to further expand our distribution network,” Cipla said.
Q3 Results Today Live Updates: Urban Company, JSW Energy, India Cements and IndusInd Bank to announce their results The North America business delivered a quarterly revenue of $167 million. FY27 pipeline includes four major respiratory launches, including gAdvair. During the quarter, the business will launch gVictoza and further expect to launch three more peptide assets in FY27. Three of the four respiratory assets are filed from US facilities.
In South Africa, private market secondary growth was at 6.3% versus the market growth of 5.7%.
Deep market focus strategy in emerging markets and Europe has laid a solid foundation, with the business delivering a growth of 7% YoY in USD terms with an uptick in both DTM and B2B categories, along with sustained overall margins.
Going ahead, Cipla said the focus will be on growing our key markets, further building flagship brands, investing in the future pipeline, as well as focusing on resolutions on the regulatory front.
Following the results, Cipla shares were trading over 4% lower at Rs 1,311.7 on NSE.